Homoharringtonine induces apoptosis and growth arrest in human myeloma cells

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1400-1406

  Lou, Yin Jun ^a   Qian, Wen Bin ^a   Jin, Jie ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Homoharringtonine; Multiple myeloma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALOID; CASPASE 3; CASPASE 8; CASPASE 9; DEXAMETHASONE; HOMOHARRINGTONINE; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BINDING ASSAY; CANCER INHIBITION; CANCER RELAPSE; CELL CYCLE ARREST; CELL GROWTH; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASES; CELL DIVISION; CELL LINE, TUMOR; DEXAMETHASONE; DRUG SYNERGISM; HARRINGTONINES; HUMANS; MULTIPLE MYELOMA; POLY(ADP-RIBOSE) POLYMERASES;

EID: 34447568292     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701411466     Document Type: Article

References (25)

1. Jackson, G., Einsele, H., Moreau, P. and Miguel, J. S. (2005) Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev, 31, pp. 591-602.
2. Kyle, R. A. and Rajkumar, S. V. (2004) Multiple myeloma. N Engl J Med, 35, pp. 1860-1873.
3. Stanford, B. L. and Zondor, S. D. (2003) Bortezomib treatment for multiple myeloma. Ann Pharmacother, 37, pp. 1825-1830.
4. Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. and Greipp, P. R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24, pp. 431-436.
5. Warrel, R. P., Coonley, C. J. and Gee, T. S. (1985) Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol, 3, pp. 617-621.
6. Luo, C. Y., Tang, J. Y. and Wang, Y. P. (2004) Homoharringtonine: A new treatment option for myeloid leukemia. Hematology, 9, pp. 259-270.
7. Feldman, E., Arlin, Z., Ahmed, T., Mittelman, A., Puccio, C. and Chun, H. (1992) Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia, 6, pp. 1185-1188.
8. Feldman, E., Arlin, Z., Ahmed, T., Mittelman, A., Puccio, C. and Chun, H. (1992) Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia, 6, pp. 1189-1191.
9. Feldman, E. J., Seiter, K. P., Ahmed, T., Baskind, P. and Arlin, Z. A. (1996) Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia, 10, pp. 40-42.
10. O'Brien, S., Kantarjian, H., Keating, M., Beran, M., Koller, C. and Robertson, L. E. (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood, 86, pp. 3322-3326.
11. O'Brien, S., Kantarjian, H., Koller, C., Feldman, E., Beran, M. and Andreeff, M. (1999) Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood, 93, pp. 4149-4153.
12. O'Brien, S., Talpaz, M., Cortes, J., Shan, J., Giles, F. J. and Faderl, S. (2002) Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer, 94, pp. 2024-2032.
13. Visani, G., Russo, D., Ottaviani, E., Tosi, P., Damiani, D. and Michelutti, A. (1997) Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia, 11, pp. 624-628.
14. Jin, J., Jiang, D. Z., Mai, W. Y., Meng, H. T., Qian, W. B. and Tong, H. Y. (2006) Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia, 20, pp. 1361-1367.
15. Levy, V., Zohar, S., Bardin, C., Vekhoff, A., Chaoui, D. and Rio, B. (2006) A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer, 95, pp. 253-259.
16. Kantarjian, H. M., Talpaz, M., Santini, V., Murgo, A., Cheson, B. and O'Brien, S. M. (2001) Homoharringtonine: History, current research, and future direction. Cancer, 92, pp. 1591-1605.
17. Zhou, J. Y., Chen, D. L., Shen, Z. S. and Koeffler, H. P. (1990) Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res, 50, pp. 2031-2035.
18. Ye, X. J. and Lin, M. F. (2004) Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci, 5, pp. 230-234.
19. Iwato, K., Kawano, M., Asaoku, H., Tanabe, O., Tanaka, H. and Kuramoto, A. (1988) Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. Blood, 72, pp. 562-566.
20. Tassone, P., Neri, P., Burger, R., Savino, R., Shammas, M. and Catley, L. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res, 11, pp. 4251-4258.
21. Yinjun, L., Jie, J., Weilai, X. and Xiangming, T. (2004) Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol, 76, pp. 199-204.
22. Ashkenazi, A. and Dixit, V. M. (1998) Death receptors: Signaling and modulation. Science, 281, pp. 1305-1308.
23. Adams, J. M. and Cory, S. (1998) The bcl-2 protein family: Arbiters of cell survival. Science, 281, pp. 1322-1326.
24. Roth, W. and Reed, J. C. (2002) Apoptosis and cancer: When BAX is TRAILing away. Nat Med, 8, pp. 216-218.
25. Cai, Z., Lin, M., Wuchter, C., Ruppert, V., Dorken, B. and Ludwig, W. D. (2001) Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia, 15, pp. 567-574.